NGL Fine Chem
NSE: NGLFINE · Pharmaceuticals
Snapshot
Unlock NGL Fine Chem's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
NGL Fine-Chem Limited is a pharmaceutical company specialising in the manufacture of active pharmaceutical ingredients (APIs) and intermediates for both veterinary and human health applications. The company offers a diverse portfolio of chemical compounds and finished dosage forms, including granules and tablets.
Business Model
The company generates revenue by manufacturing and selling specialised chemical intermediates and APIs to global markets. Its business model focuses on high-value veterinary health products alongside selective human health pharmaceutical ingredients.
- Incorporation Year:1981
Growth Outlook
Growth is driven by the expansion of its veterinary health product portfolio and the continued demand for its specialised API offerings in global markets. The company leverages its technical expertise in chemical synthesis to maintain its position in the niche animal health sector.
Key Risks
- Regulatory Compliance. The company faces stringent regulatory oversight from global health authorities regarding the quality and safety of pharmaceutical ingredients.
- Raw Material Price Volatility. Fluctuations in the cost of chemical precursors and raw materials can significantly impact profit margins.
- Export Dependency. As a global supplier, the company is exposed to geopolitical risks and changes in international trade policies.
- Competitive Pressure. The pharmaceutical API sector is highly competitive, requiring continuous investment in research and development to maintain market share.
Price
Start your research today
Unlock AI insights, financials, peers and live data on NGL Fine Chem and 5,000+ companies — free.
Key Metrics
REVENUE
₹501 Cr
TTM · consolidated
NET PROFIT
₹48 Cr
TTM · consolidated
EPS
₹77.77
TTM · consolidated
RETURN ON EQUITY
16.3%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
20.2%
TTM · consolidated
P/E
39.7x
Q4 FY26 · consolidated
EV/EBITDA
23.1x
Q4 FY26 · consolidated
EBITDA MARGIN
17.4%
TTM · consolidated
NET PROFIT MARGIN
9.0%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.4%
Q4 FY26 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap (Cr) | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
NGL Fine ChemNGLFINE | 1,338 | 39.70 | 23.05 | 36.1% | 17.4% | 16.3% | 20.2% | +115.0% |
Jagsonpal PharmaJAGSNPHARM | 1,216 | 35.45 | 21.17 | 6.9% | 24.4% | 17.3% | 22.4% | -7.9% |
Lincoln Pharma.LINCOLN | 1,173 | 13.71 | 9.06 | 7.7% | 19.5% | 12.7% | 16.4% | +7.8% |
Ind-Swift Labs.INDSWFTLAB | 1,168 | 44.47 | 17.62 | 226.0% | 14.7% | 3.4% | 4.0% | +121.7% |
Venus RemediesVENUSREM | 1,157 | 23.25 | 14.80 | 18.0% | 20.9% | 17.5% | 22.1% | +239.7% |
Hester BiosHESTERBIO | 1,150 | 36.08 | 23.45 | 6.9% | 29.0% | 17.6% | 15.2% | +31.0% |
As of Q4 FY26
Financials
NGL Fine Chem
NSE: NGLFINE · Pharmaceuticals
Snapshot
Unlock NGL Fine Chem's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
NGL Fine-Chem Limited is a pharmaceutical company specialising in the manufacture of active pharmaceutical ingredients (APIs) and intermediates for both veterinary and human health applications. The company offers a diverse portfolio of chemical compounds and finished dosage forms, including granules and tablets.
Business Model
The company generates revenue by manufacturing and selling specialised chemical intermediates and APIs to global markets. Its business model focuses on high-value veterinary health products alongside selective human health pharmaceutical ingredients.
- Incorporation Year:1981
Growth Outlook
Growth is driven by the expansion of its veterinary health product portfolio and the continued demand for its specialised API offerings in global markets. The company leverages its technical expertise in chemical synthesis to maintain its position in the niche animal health sector.
Key Risks
- Regulatory Compliance. The company faces stringent regulatory oversight from global health authorities regarding the quality and safety of pharmaceutical ingredients.
- Raw Material Price Volatility. Fluctuations in the cost of chemical precursors and raw materials can significantly impact profit margins.
- Export Dependency. As a global supplier, the company is exposed to geopolitical risks and changes in international trade policies.
- Competitive Pressure. The pharmaceutical API sector is highly competitive, requiring continuous investment in research and development to maintain market share.
Price
Loading…
Start your research today
Unlock AI insights, financials, peers and live data on NGL Fine Chem and 5,000+ companies — free.
Key Metrics
REVENUE
₹501 Cr
TTM · consolidated
NET PROFIT
₹48 Cr
TTM · consolidated
EPS
₹77.77
TTM · consolidated
RETURN ON EQUITY
16.3%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
20.2%
TTM · consolidated
P/E
39.7x
Q4 FY26 · consolidated
EV/EBITDA
23.1x
Q4 FY26 · consolidated
EBITDA MARGIN
17.4%
TTM · consolidated
NET PROFIT MARGIN
9.0%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.4%
Q4 FY26 · consolidated
Peers · Pharmaceuticals
As of Q4 FY26